INTRODUCTION
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Keywords
As these localized chemotherapeutic treatments gain acceptance, it becomes important to recognize not only their potential effects on visual outcome (4, 6, 9) , but also the cumulative effects of sequential, combined treatments, which present their own complications and warrant new discussion of management strategies.
Our case report aims to discuss this contemporary dilemma in the multi-modality eye-preserving treatment of retinoblastoma.
CASE REPORT
A 4 year-old girl with nonfamilial bilateral retinoblastoma was referred to our care, with refractory disease in her remaining eye. She had been treated elsewhere by primary enucleation, intravenous (IV) chemotherapy, laser/cryotherapy, and I-125 brachytherapy OD. Vitreous seeding and chorioretinal scarring with an inferior partial rhegmatogenous retinal detachment OD prompted referral to our center. No discrete tumor was visible, but vitreous seeding was confirmed (Figure 1 A) . The patient underwent 6 sessions of singledrug Ophthalmic Artery Infusion Chemotherapy (OAIC) (topotecan) and 2 sessions of OAIC topotecan with subtenon carboplatin. After a sub-optimal response, 2 additional sessions of single-drug OAIC (melphalan) were given. Following the treatment, the vitreous seeding resolved (Figure 1 B) , but the patient was noted to have diffuse ke ratopathy, posterior synechiae, cataract, diffuse conjunctival hyperemia, and localized inferior fornix necrosis (Figures 2 A, B) . Her keratopathy was managed with the help of a therapeutic contact lens.
Unfortunately, her vitreous seeding relapsed 6 months later ( Figure  1 C) . She then underwent IVit chemotherapy (melphalan 20 μg/0.1 mL) as previously reported (9) . The vitreous seeding resolved following the first IVit injection, but she complained of foreign body pain. She received one subsequent injection (Figure 1 D) . Examination throughout the 6 months that followed showed continued vitreous clearing.
Regardless of 3 sequential placements of Prokera ® (Biotissue, Miami, FL) and 2 tarsorrhaphies, her chronic keratopathy progressed (Figure 2 C). Eventually, the keratopathy improved and her inferior fornix healed (Figure 2 D) , but her cataract worsened, precluding a view of the fundus. Magnetic resonance imaging (MRI) showed the vitreous to be clear, prompting a subsequent uneventful cataract surgery. Fundus exam performed after the cataract removal revealed massive tumor recurrence. Therefore, the eye was enucleated. Histopathology showed the optic nerve margin to be tumor free. However she had massive invasion of the choroid inferiorly. She has been tumor free for 12 months after secondary enucleation.
DISCUSSION
Retinoblastoma presents a unique narrative on the need for effective communication between physicians and families in order to establish realistic therapeutic expectations. This discussion is of pa ramount importance to children with only one remaining eye. In modern times, physicians and families have looked to new, eye-preserving therapies to avoid enucleation. As these therapeutic options begin to be widely used, one must address the cumulative effects and associated impact of such treatments.
Our patient's clinical course reflects these concerns. On presentation, she had already undergone primary enucleation OS and intense treatment OD that included IV chemotherapy, followed by sequential aggressive local therapy (SALT) and I-125 plaque brachytherapy. Although the toxicity of these combined treatments has not been documented, it has been reported that IV chemotherapy increases the risk for radiation retinopathy following I-125 plaque therapy (11) . Although salvage of the eyes with diffuse vitreous or extensive subretinal seeding can be achieved with such treatments in a minority of cases (11) , these treatments may have contributed to retinal scarring and de tachment, which, in addition to the vitreous seeding, threatened the vision in our patient's only eye.
Our decision to use OAIC with additional periocular carboplatin as salvage therapy was based on the premise that this combination effectively delivers high-dose chemotherapy to the eye while sparing the side effects of systemic treatment. OAIC is currently used as a single or multi-drug treatment (5) . At the time we first saw this patient, our institution had initiated a protocol with topotecan (dose based on child's age) as a single agent in an attempt to minimize the side effects of Melphalan, a toxic alkylating agent. After several cycles of treatment and limited response, she was switched to Melphalan. Currently, Melphalan is being used as a single agent in some treatmentnaïve patients, using doses in the range of 3 to 5 mg, depending on (5) . Although our patient's vitreous seeding resolved, its recurrence demanded a new discussion with the family regarding further management options. The family's decision to preserve her eye prompted the use of Melphalan intravitreously.
Although the eye was tumor free, the patient faced complications resulting from her many treatments. She developed a chronic keratopathy, which caused severe, persistent pain and loss of vision. Amniotic membrane graft and limbal stem cell transplant were discussed. Her prior periocular chemotherapy had resulted in necrosis of the inferior fornix, prohibiting the suturing of an amniotic membrane graft. Although the complications of periocular carboplatin administration have been reported, these complications tend to be variable and dose-dependent (12) . The use of periocular carboplatin was thoroughly discussed and was concluded to be a good option based on the reported synergy with topotecan (13) . Limbal stem cell transplant from the patient's mother was deemed unsuitable. Therefore, the focus shifted toward the placement of Prokera ® , a double amniotic membrane graft with implantation similar to a contact lens. Sequen tial placements of Prokera ® healed the previously necrotic inferior fornix. Unfortunately, the patient's cataract and small pupil, which severely limited her vision, precluded fundus examination and our ability to monitor any tumor recurrence. Knowing the risks of cataract surgery, the patient's parents chose to proceed with an MRI. After having put much effort to eradicate her RB, the final decision to enucleate her remaining eye was very difficult. However, the tumor recurrence left us with no other choice.
Modern management of retinoblastoma requires that physicians be aware of the benefits and limitations of new eye-preserving therapies. These novel treatment modalities require a multi-disciplinary, open approach with families. As seen with our patient's chronic keratopathy and secondary cataract, the cumulative side effects of multiple therapies are still unknown and have limited our management options. This is of particular concern when complications preclude active assessment of tumor recurrence. Although tumor suppression is the main treatment goal, it is imperative that physicians consider the long-term consequences of these progressive therapies and their impact on the lives of these children. Finally, it is important to realize that, at times, even extensive efforts may fail to save the child's eye. In doing so, collectively, we will be more mindful of the treatment-associated morbidity and will anticipate the potential side effects and complications to possibly achieve better outcomes and improve patients' quality of life. 
